Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.

For the third time in four years, CNBC has ranked North Carolina as “America’s Top State for Business” in 2025.

Merck’s potential for upside hinges on its ability to execute on several key fronts: successfully advancing its pipeline, expanding geographically, and making strategic acquisitions.

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme Therapeutics.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out why MRK stock is a Strong Buy.

Merck KGaA (Merck), headquartered in Darmstadt, Germany, and Israel-based Peregrine Ventures have announced a collaboration agreement in which Merck will become a strategic partner in one of Peregrine ...

Merck has announced plans to build a biologics manufacturing facility in Wilmington, Delaware. The company, which develops and produces medicines and vaccines, has invested $1 billion in the project, ...

The Wilmington Alumnae Chapter of Delta Sigma Theta partners with Cape Fear Habitat for Humanity to volunteer their service.